Compare Ascendis Pharma A/S (ASND) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Williams Companies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Williams Companies Inc trades at $76.05 (market cap $91.75B). The key difference: Williams Companies Inc is far larger — about 5.2× Ascendis Pharma A/S's market cap, and Williams Companies Inc pays a 2.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WMB | |
|---|---|---|
Market Cap | $17.74B | $91.75B |
Sector | Health | Energy |
52-Week High | $277.18 | $79.40 |
52-Week Low | $163.32 | $56.51 |
Enterprise Value | $18.11B | $121.14B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Williams Companies (WMB) trades at $75.02, down 0.57% on the day, with strong analyst consensus (79% buy ratings) and a $85.58 price target suggesting 14% upside. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust profitability (23.4% net margin) and positive cash flow trends. Recent news highlights WMB's potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure.
WMB presents a compelling investment case with stable fee-based revenue, dividend growth potential, and strategic expansion plans. Key risks include execution of large acquisitions, commodity price volatility exposure, and high debt levels. The current valuation at 32.9x P/E appears elevated but justified by strong earnings growth and sector-leading margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
